NAVAMEDIC (NAVA.OL) Stock Fundamental Analysis
OSL:NAVA - Euronext Oslo - NO0010205966 - Common Stock - Currency: NOK
We assign a fundamental rating of 3 out of 10 to NAVA. NAVA was compared to 53 industry peers in the Pharmaceuticals industry. NAVA has a bad profitability rating. Also its financial health evaluation is rather negative. NAVA is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
NAVA had positive earnings in the past year.
NAVA had positive earnings in 4 of the past 5 years.
In multiple years NAVA reported negative operating cash flow during the last 5 years.
1.2 Ratios
The Return On Assets of NAVA (0.26%) is worse than 64.15% of its industry peers.
NAVA has a worse Return On Equity (0.54%) than 62.26% of its industry peers.
NAVA has a Return On Invested Capital of 6.99%. This is comparable to the rest of the industry: NAVA outperforms 45.28% of its industry peers.
NAVA had an Average Return On Invested Capital over the past 3 years of 9.81%. This is significantly below the industry average of 15.44%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.26% | ||
| ROE | 0.54% | ||
| ROIC | 6.99% |
ROA(3y)2.86%
ROA(5y)0.48%
ROE(3y)5.35%
ROE(5y)0.74%
ROIC(3y)9.81%
ROIC(5y)N/A
1.3 Margins
NAVA's Profit Margin of 0.24% is on the low side compared to the rest of the industry. NAVA is outperformed by 64.15% of its industry peers.
In the last couple of years the Profit Margin of NAVA has declined.
NAVA's Operating Margin of 5.98% is on the low side compared to the rest of the industry. NAVA is outperformed by 62.26% of its industry peers.
In the last couple of years the Operating Margin of NAVA has grown nicely.
NAVA has a worse Gross Margin (39.30%) than 79.25% of its industry peers.
NAVA's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.98% | ||
| PM (TTM) | 0.24% | ||
| GM | 39.3% |
OM growth 3Y13.14%
OM growth 5YN/A
PM growth 3Y4.04%
PM growth 5Y-56.03%
GM growth 3Y-0.68%
GM growth 5Y5.2%
2. Health
2.1 Basic Checks
NAVA has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for NAVA has been increased compared to 1 year ago.
The number of shares outstanding for NAVA has been increased compared to 5 years ago.
The debt/assets ratio for NAVA has been reduced compared to a year ago.
2.2 Solvency
NAVA has a Debt/Equity ratio of 0.33. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.33, NAVA is in the better half of the industry, outperforming 66.04% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.33 | ||
| Debt/FCF | N/A | ||
| Altman-Z | N/A |
ROIC/WACC0.89
WACC7.84%
2.3 Liquidity
NAVA has a Current Ratio of 1.42. This is a normal value and indicates that NAVA is financially healthy and should not expect problems in meeting its short term obligations.
NAVA has a Current ratio (1.42) which is comparable to the rest of the industry.
A Quick Ratio of 0.84 indicates that NAVA may have some problems paying its short term obligations.
NAVA has a Quick ratio of 0.84. This is in the lower half of the industry: NAVA underperforms 64.15% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.42 | ||
| Quick Ratio | 0.84 |
3. Growth
3.1 Past
NAVA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -62.23%.
The earnings per share for NAVA have been decreasing by -50.19% on average. This is quite bad
Looking at the last year, NAVA shows a small growth in Revenue. The Revenue has grown by 3.80% in the last year.
The Revenue has been growing by 23.00% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-62.23%
EPS 3Y22.2%
EPS 5Y-50.19%
EPS Q2Q%-2161.58%
Revenue 1Y (TTM)3.8%
Revenue growth 3Y24.05%
Revenue growth 5Y23%
Sales Q2Q%4.7%
3.2 Future
Based on estimates for the next years, NAVA will show a very strong growth in Earnings Per Share. The EPS will grow by 30.84% on average per year.
NAVA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 16.69% yearly.
EPS Next Y-43.8%
EPS Next 2Y38.37%
EPS Next 3Y40.99%
EPS Next 5Y30.84%
Revenue Next Year9.98%
Revenue Next 2Y10.59%
Revenue Next 3Y10.61%
Revenue Next 5Y16.69%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 314.29, NAVA can be considered very expensive at the moment.
Based on the Price/Earnings ratio, NAVA is valued a bit more expensive than the industry average as 67.92% of the companies are valued more cheaply.
When comparing the Price/Earnings ratio of NAVA to the average of the S&P500 Index (26.25), we can say NAVA is valued expensively.
With a Price/Forward Earnings ratio of 29.75, NAVA can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, NAVA is valued a bit more expensive than the industry average as 67.92% of the companies are valued more cheaply.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.15, NAVA is valued a bit more expensive.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 314.29 | ||
| Fwd PE | 29.75 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as NAVA's earnings are expected to grow with 40.98% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.37%
EPS Next 3Y40.99%
5. Dividend
5.1 Amount
No dividends for NAVA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
OSL:NAVA (5/30/2025, 7:00:00 PM)
22
+0.1 (+0.46%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners36.11%
Inst Owner ChangeN/A
Ins Owners19.89%
Ins Owner ChangeN/A
Market Cap388.52M
Analysts82.5
Price Target32.64 (48.36%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-9.93%
Min Revenue beat(2)-17.93%
Max Revenue beat(2)-1.92%
Revenue beat(4)1
Avg Revenue beat(4)-6.45%
Min Revenue beat(4)-17.93%
Max Revenue beat(4)3.23%
Revenue beat(8)3
Avg Revenue beat(8)-0.95%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.88%
PT rev (3m)-5.88%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.97%
Revenue NQ rev (1m)-1.34%
Revenue NQ rev (3m)-0.98%
Revenue NY rev (1m)-0.78%
Revenue NY rev (3m)-0.26%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 314.29 | ||
| Fwd PE | 29.75 | ||
| P/S | 0.73 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.62 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)0.07
EY0.32%
EPS(NY)0.74
Fwd EY3.36%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS30.09
BVpS13.61
TBVpS-0.63
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.26% | ||
| ROE | 0.54% | ||
| ROCE | 9.07% | ||
| ROIC | 6.99% | ||
| ROICexc | 8.24% | ||
| ROICexgc | 54.01% | ||
| OM | 5.98% | ||
| PM (TTM) | 0.24% | ||
| GM | 39.3% | ||
| FCFM | N/A |
ROA(3y)2.86%
ROA(5y)0.48%
ROE(3y)5.35%
ROE(5y)0.74%
ROIC(3y)9.81%
ROIC(5y)N/A
ROICexc(3y)12.15%
ROICexc(5y)N/A
ROICexgc(3y)61.67%
ROICexgc(5y)N/A
ROCE(3y)12.74%
ROCE(5y)N/A
ROICexcg growth 3Y48.41%
ROICexcg growth 5YN/A
ROICexc growth 3Y9.73%
ROICexc growth 5YN/A
OM growth 3Y13.14%
OM growth 5YN/A
PM growth 3Y4.04%
PM growth 5Y-56.03%
GM growth 3Y-0.68%
GM growth 5Y5.2%
F-ScoreN/A
Asset Turnover1.08
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.33 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.42 | ||
| Quick Ratio | 0.84 | ||
| Altman-Z | N/A |
F-ScoreN/A
WACC7.84%
ROIC/WACC0.89
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-62.23%
EPS 3Y22.2%
EPS 5Y-50.19%
EPS Q2Q%-2161.58%
EPS Next Y-43.8%
EPS Next 2Y38.37%
EPS Next 3Y40.99%
EPS Next 5Y30.84%
Revenue 1Y (TTM)3.8%
Revenue growth 3Y24.05%
Revenue growth 5Y23%
Sales Q2Q%4.7%
Revenue Next Year9.98%
Revenue Next 2Y10.59%
Revenue Next 3Y10.61%
Revenue Next 5Y16.69%
EBIT growth 1Y34.85%
EBIT growth 3Y40.35%
EBIT growth 5YN/A
EBIT Next Year22.79%
EBIT Next 3Y27.28%
EBIT Next 5Y26.96%
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A